Japan’s Kyowa Kirin has reached an agreement to buy Orchard Therapeutics of the UK in a deal valued at up to $478 million, ahead of an FDA decision on the biotech’s lead g
German pharma Grünenthal has started the process of taking ownership of 13 ageing medicines developed by Japan's Kyowa Kirin, which are currently sold by affiliate companies across Europe.<
Despite reporting proof-of-concept results in a mid-stage trial, Kyowa Kirin has decided to discontinue development of its Parkinson's disease candidate KW-6356, a drug in the adenosine A2A
NICE has reversed an earlier decision not to recommend NHS use of Kyowa Kirin's Poteligeo for two rare blood cancers, ending the threat of a north-south divide in access to the drug in the
Fresh from its takeover of Alexion, AstraZeneca has picked up a recommendation in the EU for an expansion of the label of Ultomiris, one of the main assets behind the
A north-south divide has emerged in UK medicines access after the Scottish Medicines Consortium (SMC) okayed Kyowa Kirin's Poteligeo for two rare blood cancers, a few weeks after the drug w
South Korea’s Hyundai Bioscience is preparing to start clinical trials of what it hopes could become the first antiviral treatment for dengue fever, a mosquito-borne viral
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.